Life Science News

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

Lucid Group, Inc. (NASDAQ:LCID)
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
Lead Plaintiff Deadline: May 31, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid's business and operations. Specifically, the Company overstated its production capabilities while concealing that "extraordinary supply chain and logistics challenges" were hampering Lucid's operations. As a result of the defendants' wrongful acts and omissions, and the significant decline in the market value of Lucid's common stock, Lucid investors have suffered significant damages.

Learn about your recoverable losses in LCID: https://www.kleinstocklaw.com/pslra-1/lucid-group-inc-loss-submission-form?id=27730&from=1

International Business Machines Corporation (NYSE:IBM)
Class Period: April 4, 2017 - October 20, 2021
Lead Plaintiff Deadline: June 6, 2022

According to the complaint, International Business Machines Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.

Learn about your recoverable losses in IBM: https://www.kleinstocklaw.com/pslra-1/international-business-machines-corporation-loss-submission-form?id=27730&from=1

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Class Period: May 7, 2021 - February 25, 2022
Lead Plaintiff Deadline: June 14, 2022

The AUPH lawsuit alleges Aurinia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in AUPH: https://www.kleinstocklaw.com/pslra-1/aurinia-pharmaceuticals-inc-loss-submission-form?id=27730&from=1

The Klein Law Firm, Wednesday, May 25, 2022, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/702750/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-LCID-IBM-and-AUPH

News Provided by ACCESSWIRE IA via QuoteMedia

AUP:CA,AUPH
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

  • Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication.
  • Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT™ HLA types, supporting BriaCell's platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.
  • The clinical data, previously reported, included rapid tumor reduction and extended survival.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCell's lead candidate, Bria-IMT™. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCell's approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT™ against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.

"We are thrilled to see the congruence of our scientific insights and the clinical activity of our immunotherapy in advanced breast cancer patients," stated Dr. Williams, BriaCell's President & CEO. "This paper highlights our findings of rapid tumor shrinkage in multiple anatomic locations including difficult to treat sites like the brain. We are even more excited to see the potential positive effect on survival in these patients. Having these scientific and clinical findings published in such a highly regarded journal is a significant achievement for BriaCell. The results support our approach for selecting patients most likely to benefit from our immunotherapy. This undergirds our current strategy of building a pipeline of off-the-shelf personalized immunotherapies as potentially safe and effective treatments for advanced breast cancer and other cancers," Dr. Williams added.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV –

– If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer

The findings also show majority of HCPs view treating CLL patients as different from treating other cancers - The emotional complexities of this slow-growing cancer point to patient and caregiver need for greater support from HCPs at time of diagnosis

NORTH CHICAGO, Ill. , June 24, 2022 /PRNewswire/ -- AbbVie today shared findings from the newly launched Emotional Impact Report , a survey of more than 300 chronic lymphocytic leukemia (CLL) patients, caregivers and healthcare providers (HCPs), which uncovered insights about the emotional journey associated with a CLL diagnosis.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AbbVie Declares Quarterly Dividend

The board of directors of ABBVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.

The cash dividend is payable August 15, 2022 , to stockholders of record at the close of business on July 15, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Treatment With Hepcludex® Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks

-

Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex ® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. Findings from the study underscore the efficacy and safety of bulevirtide for the treatment of chronic HDV and are being presented today in the International Liver Congress (ILC) 2022 Official Press Program. In addition, Week 48 data demonstrating the positive impact of bulevirtide on patient-reported outcomes (PROs) in people living with chronic HDV will also be presented. Together, these data reinforce the clinical utility of bulevirtide as monotherapy for the treatment of chronic HDV. There are currently no other approved treatment options for HDV and people living with HDV typically have a poor prognosis.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×